Reference | </br>1:HPLC determination of pirenzepine dihydrochloride in rabbit aqueous humor. Tu J, Li P, Yang X, Pang H.J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):300-3. PMID: 16002348 </br>2:Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol). Morris A, Brown P, Ali MR, Lane M, Palmer R.N Z Med J. 1988 Oct 26;101(856 Pt 1):651-4. PMID: 3054641 </br>3:[Promotion of gastrointestinal absorption of pirenzepine dihydrochloride in the rat. I]. Nakagawa H, Nishiyama K, Matsumoto S, Hamano K, Fukui Y, Goto S.Yakugaku Zasshi. 1988 Jul;108(7):669-73. Japanese. No abstract available. PMID: 3241303 </br>4:Controlled double-blind study of the therapeutic effect of pirenzepine dihydrochloride in duodenal ulcer. Phase III study. Ishimori A, Yamagata S.Arzneimittelforschung. 1986 Jun;36(6):980-3. PMID: 3527182 </br>5:Spectrophotometric determination of pirenzepine dihydrochloride using delta A method. Wahbi AM, Abounassif MA, el-Obeid HA, Gad-Kariem EA.Farmaco Prat. 1985 Oct;40(10):334-8. No abstract available. PMID: 3840745 </br>6:Postprandial pancreatic exocrine secretion in dogs after oral administration of pirenzepine dihydrochloride. Madrid JA, Salido GM, Martinez de Victoria E, Mañas M, Mataix FJ.Arzneimittelforschung. 1985;35(10):1560-2. PMID: 2416323 </br>7:Therapeutic effect of pirenzepine dihydrochloride on gastric ulcer evaluated by a double-blind controlled clinical study. Phase III study. Ishimori A, Yamagata S.Arzneimittelforschung. 1982;32(5):556-65. PMID: 7049190 </br>8:Actions of pirenzepine-dihydrochloride (LS-519 Cl) on gastric juice secretion, gastric motility and experimental gastric ulcer. Matsuo Y, Seki A.Arzneimittelforschung. 1979;29(7):1028-35. No abstract available. PMID: 582994
|